EUVIMEDEUVIMED entdecken
Crossref

Impact of Post-Therapy Acquisition Time on RECIP 1.0 Classification in [¹⁷⁷Lu]Lu-PSMA SPECT/CT

F Shenas, W Lehnert, M-S Dependehner, A S Kisters, A Marandi, I Apostolova, S Klutmann, R Braren, A Karimzadeh

Nuklearmedizin - NuclearMedicine · 01.04.2026 · 65 (02) · 136-137

DOI: 10.1055/s-0046-1818266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.04.2026. Verfasst von F Shenas und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ziel/Aim: Recent analyses have demonstrated the prognostic value of post-therapy [¹⁷⁷Lu]Lu-PSMA SPECT/CT using the visual response framework of RECIP 1.0, which was originally developed for PSMA-ligand PET/CT. However, the potential influence of different post-therapy acquisition times remains uncertain. Therefore, this retrospective analysis aimed to evaluate the agreement between [¹⁷⁷Lu]Lu-PSMA SPECT/CT acquired at 2–4 h and 24 h post-therapy. Methodik/Methods: Sixty-four patients with metastatic castration-resistant prostate cancer (mCRPC) who received at least two cycles of [¹⁷⁷Lu]Lu-PSMA radioligand therapy between December 2019 and March 2024 and had both 2–4 h and 24 h post-therapy SPECT/CT acquisitions available were retrospectively included. Paired baseline and interim SPECT/CT scans after two therapy cycles were visually classified according to RECIP 1.0, and agreement between the 2–4 h and 24 h post-therapy acquisitions was evaluated using the McNemar and Bowker tests. Ergebnisse/Results: Progressive disease (PD) was observed in 8 patients (12.5%) on the 2–4 h scans and in 9 patients (14.1%) on the 24 h scans, with 8 cases (88.9%) showing concordant classification (p=1.00). New lesions were detected in 11 patients (17.2%) at 2–4 h and in 17 patients (26.6%) at 24 h, with 11 cases (64.7%) concordant (p=0.031). Overall concordance across all RECIP 1.0 response categories was observed in 55 of 64 patients (85.9%) (p=0.37). Discrepancies mainly involved borderline cases between partial response and stable disease, with one case progressing from complete to partial response and another from stable disease to PD. No patient showed improvement from progressive to a less advanced category. Schlussfolgerungen/Conclusion: Our results indicate that RECIP 1.0–based visual assessment provides largely consistent classifications between the 2–4 h and 24 h post-therapy [¹⁷⁷Lu]Lu-PSMA SPECT/CT scans. However, new lesions were more frequently detected on the 24 h scans, while remaining discrepancies were primarily confined to borderline classifications between partial response and stable disease. Publication History Article published online: 02 April 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Zitieren

APA

Shenas, F., Lehnert, W., Dependehner, M., Kisters, A. S., Marandi, A., Apostolova, I., Klutmann, S., Braren, R., & Karimzadeh, A. (2026). Impact of Post-Therapy Acquisition Time on RECIP 1.0 Classification in [¹⁷⁷Lu]Lu-PSMA SPECT/CT. Nuklearmedizin - NuclearMedicine, 65(02), 136-137. https://doi.org/10.1055/s-0046-1818266

Vancouver

Shenas F, Lehnert W, Dependehner M, Kisters AS, Marandi A, Apostolova I, et al. Impact of Post-Therapy Acquisition Time on RECIP 1.0 Classification in [¹⁷⁷Lu]Lu-PSMA SPECT/CT. Nuklearmedizin - NuclearMedicine. 2026;65(02):136-137. doi:10.1055/s-0046-1818266

BibTeX
@article{Shenas2026,
  author = {Shenas, F and Lehnert, W and Dependehner, M-S and Kisters, A S and Marandi, A and Apostolova, I and Klutmann, S and Braren, R and Karimzadeh, A},
  title = {Impact of Post-Therapy Acquisition Time on RECIP 1.0 Classification in [¹⁷⁷Lu]Lu-PSMA SPECT/CT},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2026},
  volume = {65},
  number = {02},
  pages = {136--137},
  doi = {10.1055/s-0046-1818266}
}
Kostenlos starten →